Loading…
Cue Biopharma, Inc. is projected to decline to $18.83 by 2027, a -8% move from its current price of $20.44. CUE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $18.74 | $20.44 | $22.29 | 0.00% |
| May 30 | $18.08 | $20.44 | $23.10 | 0.00% |
| May 31 | $17.59 | $20.44 | $23.75 | +0.01% |
| Jun 1 | $17.18 | $20.44 | $24.31 | +0.01% |
| Jun 2 | $16.83 | $20.44 | $24.81 | +0.01% |
| Jun 3 | $16.53 | $20.44 | $25.28 | +0.01% |
| Jun 4 | $16.25 | $20.44 | $25.71 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.25 | $20.44 | $25.71 | +0.02% |
| Week 2 | $14.78 | $20.44 | $28.28 | +0.03% |
| Week 3 | $13.74 | $20.44 | $30.42 | +0.05% |
| Week 4 | $12.92 | $20.45 | $32.36 | +0.06% |
| Week 5 | $12.24 | $20.45 | $34.16 | +0.08% |
| Week 6 | $11.66 | $20.45 | $35.88 | +0.09% |
| Week 7 | $11.15 | $20.46 | $37.54 | +0.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. It is headquartered in Boston, Massachusetts and was incorporated in 2014, later changing its name to Cue Biopharma, Inc. in October 2016.
The company’s lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. It also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer.
Cue Biopharma has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine.
Cue Biopharma, Inc. (CUE) is a healthcare company currently trading at $21.47 per share with a market capitalization of $86.86M, and it ranks 4318 by market size. The current price and market position place it among smaller-cap healthcare names with a clinical-stage portfolio across multiple immuno-oncology and autoimmune programs.
The latest forecast shows a wide year-by-year range, with near-term values hovering around the current price and longer-term upside potential emerging in the 2030s and beyond. The model projects a multi-year path that includes upticks and pullbacks, culminating in substantial upside by 2050.
A major floor 74.0% below — a decisive break under it would weaken the trend.
The nearest floor, 39.1% below — buyers have tended to step in here.
The nearest ceiling, 74.8% above — a clean break opens room to run.
A major ceiling 125.8% above — clearing it would confirm fresh momentum.
Key CUE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CUE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.49 | Sell | $20.87 | Sell |
| MA 10 | $22.20 | Sell | $22.23 | Sell |
| MA 20 | $25.51 | Sell | $22.66 | Sell |
| MA 50 | $17.24 | Buy | $19.25 | Buy |
| MA 100 | $13.47 | Buy | $16.81 | Buy |
| MA 200 | $16.77 | Buy | $17.78 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.92 | Neutral |
| Stoch RSI (14) | 3.48 | Buy |
| CCI (20) | -56.03 | Neutral |
| Williams %R (14) | -97.42 | Info |
| MACD (12,26,9) | -1.46 | Sell |
| ROC (12) | -41.61 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 2.58 | Buy |
| TRIX (15) | 1.58 | Buy |
| Awesome (5,34) | -1.49 | Sell |
| Ultimate (7,14,28) | 29.59 | Buy |
| Momentum (10) | -8.83 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 20.01 | Buy |
| ADX (14) | 17.42 | Neutral |
| ATR (14) | 1.90 | Info |
30-day technical picture: sentiment is NEUTRAL with RSI(14) at 50. The SMA50 is $16.79 and the SMA200 is $16.82, indicating a near-term price average around the mid-teens relative to the current level. Support sits at $12.45 and resistance at $35.73, framing a broad range for the next month.
The 30-day price range spans from $11.78 to $39.14, underscoring notable volatility in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.31 | $20.44 | $25.76 | 0% | Neutral | |
| $13.55 | $18.83 | $28.32 | -8% | Neutral | |
| $10.44 | $15.40 | $24.61 | -25% | Bearish | |
| $11.40 | $17.70 | $29.67 | -13% | Neutral | |
| $12.86 | $20.92 | $36.47 | +2% | Neutral | |
| $14.34 | $24.38 | $43.97 | +19% | Neutral | |
| $15.97 | $28.30 | $52.61 | +39% | Bullish | |
| $13.03 | $24.04 | $45.91 | +18% | Neutral | |
| $11.10 | $21.30 | $41.70 | +4% | Neutral | |
| $11.75 | $23.44 | $46.95 | +15% | Neutral | |
| $15.63 | $34.74 | $76.42 | +70% | Bullish | |
| $31.90 | $70.89 | $163.04 | +247% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.31 | $20.44 | $24.50 | +0.00% |
| June 2026 | $17.76 | $21.30 | $26.47 | +4.22% |
| July 2026 | $16.79 | $20.48 | $26.10 | -3.86% |
| August 2026 | $16.61 | $20.53 | $26.68 | +0.28% |
| September 2026 | $16.82 | $21.03 | $27.75 | +2.39% |
| October 2026 | $15.70 | $19.82 | $26.53 | -5.71% |
| November 2026 | $14.48 | $18.45 | $24.99 | -6.95% |
| December 2026 | $14.63 | $18.80 | $25.76 | +1.93% |
Click any year to see its month-by-month CUE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CUE to range from $5.31 to $25.76 through 2026. The $20.44 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CUE price prediction for 2027 points to an average of $18.83 (low $13.55, high $28.32) — a potential decline of -8% on today's $20.44. A consolidation phase looks the most probable path here.
In 2028, CUE is projected to trade between $10.44 and $24.61, averaging $15.40 — a potential decline of -25% from today's $20.44. That is -18% versus the projected 2027 average. A cyclical pullback looks likely — prices rarely move in a straight line.
Cue Biopharma, Inc.'s 2029 outlook centres on $17.70, within a $11.40 to $29.67 range. That is up +15% on the projected 2028 average. That marks a -13% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, CUE could reach as high as $36.47, with a base case around $20.92 and support toward $12.86 — roughly +2% from $20.44. Price action looks broadly range-bound.
Expect CUE to range from $14.34 to $43.97 through 2031. The $24.38 average target implies a +19% move from current prices. That is up +17% on the projected 2030 average. A consolidation phase looks the most probable path here.
The CUE price prediction for 2032 points to an average of $28.30 (low $15.97, high $52.61) — a potential gain of +39% on today's $20.44. Momentum favours further upside here.
In 2033, CUE is projected to trade between $13.03 and $45.91, averaging $24.04 — a potential gain of +18% from today's $20.44. That is -15% versus the projected 2032 average. A consolidation phase looks the most probable path here.
Cue Biopharma, Inc.'s 2034 outlook centres on $21.30, within a $11.10 to $41.70 range. That is -11% versus the projected 2033 average. That marks a +4% change versus current levels. Price action looks broadly range-bound.
By 2035, CUE could reach as high as $46.95, with a base case around $23.44 and support toward $11.75 — roughly +15% from $20.44. A consolidation phase looks the most probable path here.
Expect CUE to range from $15.63 to $76.42 through 2040. The $34.74 average target implies a +70% move from current prices. That is up +48% on the projected 2035 average. Momentum favours further upside here.
The CUE price prediction for 2050 points to an average of $70.89 (low $31.90, high $163.04) — a potential gain of +247% on today's $20.44. Buyers look set to stay in control over this stretch.
Investing $1,000 in CUE today (≈ 48.93565 CUE) could be worth
$3,468.86
+$2,468.86 (+247%) by 2050 · US Dollar
Based on the average projected CUE price of $70.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CUEwould be worth at today's price.
$1,000 invested in CUE on May 27, 2025 (≈ 50.276522 CUE) would be worth
$1,027.4
+$27.4 (+2.7%) today · 1.03× · US Dollar
Based on a CUE entry price of $19.89 vs. today's $20.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $20.43 | $1,000.24 | +0.0% |
| 1 month ago | $17.93 | $1,139.71 | +14.0% |
| 3 months ago | $8.64 | $2,365.16 | +136.5% |
| 6 months ago | $18.9 | $1,081.22 | +8.1% |
| 1 year ago | $19.89 | $1,027.4 | +2.7% |
| All time (5.0y) ago | $419.7 | $48.69 | -95.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CUE forecast.
Our base-case forecast reaches $41.00 around 2050.
Implied market cap at $41.00: $165.87M
The multi-year forecast shows a path of modest to strong upside at later horizons. In 2030, the average price is projected at $20.32 with a max of $35.44 and a min of $12.48, yielding a negative ROI of -5.4% and a NEUTRAL sentiment.
In 2040, the average rises to $33.84 with a max of $74.45 and a min of $15.23, delivering a 57.6% ROI and a BULLISH sentiment. By 2050, the average reaches $67.10 and the max/ min are $154.33/$30.19, for an estimated ROI of 212.5% and a BULLISH sentiment. These figures reflect a history of near-term volatility (illustrated by negative ROIs in several early years) followed by meaningful longer-term upside potential, contingent on evolving fundamental and market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $20.32 with a min of $12.48 and a max of $35.44, and a ROI of -5.4%. The sentiment for 2030 is NEUTRAL.
The year-by-year forecast includes neutral and bearish periods in the near term (for example, 2027 ROI -9.2% and 2028 ROI -26.4%), with upside emerging later (2032 ROI 32.5% and 2040 ROI 57.6%). The 2026 average aligns with the current price at $21.47, indicating no guaranteed gains and meaningful uncertainty.
The forecast max reaches $154.33 in 2050, with $74.45 in 2040 and $35.44 in 2030. This suggests a path to or above $100 could occur by 2050 within the model’s projected max, though it is not guaranteed.
Current price is $21.47 and market cap is $86.86M, with a rank of 4318.
The 30-day picture shows NEUTRAL sentiment, RSI(14) at 50, SMA50 of $16.79, SMA200 of $16.82, with support at $12.45 and resistance at $35.73. The 30-day range is from $11.78 to $39.14, reflecting notable near-term volatility.
Cue Biopharma, Inc. Community Discussion
0Share your Cue Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.